Linear DNA templates for rapid, versatile, and reliable mRNA production by in vitro transcription
Linear dsDNA Up to 5.5 kb, with poly(A) tail
No downstream processing steps
Cell-free production: no risks of bioburden and endotoxins
Ships as fast as 10 business days
Built using Elegen’s patented cell-free DNA manufacturing technology,
ENFINIA IVT Ready DNA templates offer a wide range of complexity without the pitfalls of plasmid cloning. Expand sequence diversity while reducing timelines and eliminating the risks of contamination and recombination.
Prophylactic Vaccines
Evaluate and select from more mRNA designs faster. ENFINIA IVT Ready DNA enables rapid mRNA screening, selection, and iteration—without the delays, variability, and endotoxin risks associated with plasmid-derived templates. Effectively prioritize leads to ensure the timely development of vaccines in response to infectious diseases.
Protein Replacement Therapy
ENFINIA IVT Ready DNA enables fast and reliable mRNA production for therapeutic protein expression, without the complexity or cost of protein manufacturing or the risks of gene integration. Developers can accelerate timelines and deliver safer, more effective protein replacement therapies faster.
Personalized Cancer Vaccines
Rapidly test longer, polycistronic, and more complex neoantigen sequences without ever touching a cell. ENFINIA IVT Ready DNA enables swift, reliable, and scalable production of mRNA sequences with greater stability and translation efficiency. Developers can refine their vaccines while tumor profiles remain actionable.
Cell Therapies & Genome Editing
Utilize IVT Ready DNA for next-generation cell therapies, such as mRNA-based CAR-T cells for cancer and autoimmune diseases. Leverage the large capacity of ENFINIA templates to encode genome editing modalities—such as Cas9 and base editors—for correcting genetic diseases and engineering the genome in vivo.
| Specification | Standard Complexity | High Complexity |
|---|---|---|
| Sequence Length (w/o poly(A) tail) | 1000-5,500 bp | 1000-5,500 bp |
| Overall GC Content | 25-65% | 25-76% |
| 100 bp GC Content | 22-75% | 12-83% |
| Local GC Variation | up to 60% | up to 70% |
| Repeats | up to 20 bp | up to 150 bp |
| Homopolymers* (not including poly(A) tail) | Up to 7 bases for G/C, Up to 8 bases for A/T | Up to 15 bases for G/C, Up to 30 bases for A/T |
*Elegen’s QC methods currently used for ENFINIA IVT Ready DNA may not reliably measure homopolymer sequences longer than 10 bp, except for the poly(A) tail. An accepted sequence containing a homopolymer that is longer than 10 bp may contain molecules where the homopolymer is shorter or longer than expected.
| Tail Type | Position 1 | Position 2 | Position 3 | Position 4 | Position 5 | Position 6 |
|---|---|---|---|---|---|---|
| Continuous Tails | A70 | A90 | A100 | A110 | A120 | A130 |
| Tail Type | Position 1 | Position 2 |
|---|---|---|
| Segmented Tails (two deoxyadenosine homopolymers separated by a 10 bp UGC Linker, 5'-GCATATGACT-3') | A30-Linker-A70 | A30-Linker-A90 |
